Updated 9/22/2018 with information from the September 2018 Fact Sheet

--------------------------------

EASD 2018 (European Association for the Study of Diabetes) October 1-5, 2018

Presentation October 3: "Apabetalone (RVX-208) an epigenetic modifier lowers risk of MACE in diabetes patients with CVD by affecting monocyte adhesion to endothelial cells." Abstract here.

BIO Investor Forum, October 17-18, 2018, San Francisco 

Resverlogix and Zenith both on the presenting company list as of 9/22/2018

ASN 2018 Kidney Week (American Society for Nephrology) October 23-28, 2018; San Diego, CA

On the September 2018 Resverlogix Fact Sheet, but I could not find anything on the conference schedule for Resverlogix.

CTAD 2018 (11TH Clinical Trials on Alzheimer's Disease) October 24-27, 2018; Barcelona, Spain 

Poster presentation  "Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease." Abstract not available

BIO-Europe November 5-7, 2018; Copenhagen, Denmark

Resverlogix and Zenith both on the presenting company list as of 9/22/2018

AHA 2018 (American Heart Association) November 10-12, 2018; Chicago, IL

Presentation #1 November 11: "Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study." Abstract currently embargoed.

Presentation #1 November 12: "Apabetalone (RVX-208) Suppresses Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and LPS-Challenged Mouse Liver and Monocyte Adhesiveness to Activated Endothelial Cells." Abstract currently embargoed.

H1 2019 events to keep an eye on

Biotech Showcase January 7-9, 2018; San Francisco, CA

American College Cardiology (ACC) March 16-18, 2019; New Orleans, LA (note: Late-Breaking Clinical Trial Submissions are open Wednesday, Oct. 24 – Wednesday, Dec. 5, 2018). This is prime time possiblility for BETonMACE. First big cardio conference of the new year. Many big cardio outcomes trials present full trial results here.

BIO-Europe Spring March 25-27, 2018; Vienna, Austria

Vascular Discovery: From Genes to Medicine (Formerly ATVB:PVD): May 2019

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA): June 2019

BIO-International June 2019

American Diabetes Association (ADA) June 2019